Aciont® Inc. is a specialty biopharmaceutical company focused on commercializing localized, non-invasive, controlled and sustained release back-of-the-eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. The underpinning technology platform incorporates a novel sustained release methodology for water soluble or poorly soluble drugs (commonly susceptible to ocular clearance effects) as part of a non-invasive or topical drug delivery system. The company's Visulex technology employs a passive diffusion-based sustained release system that has demonstrated superior pharmacokinetic profiles over other technologies that deliver water soluble and poorly soluble agents passively and actively (iontophoresis) to the posterior pole of the eye; Visulex has been shown to treat retinal disease under a known preclinical model using a variety of proprietary pharmaceutical formulations and methods. Many of the leading back of the eye drug delivery technologies are invasive in nature because they target the eyeâs interior regions such as the vitreous or retina, which often cannot be reached via conventional methods (e.g., eye drops). Aciont's goal is to provide a non-invasive alternative to these drug delivery technologie
